Please login to the form below

Not currently logged in
Email:
Password:

MOV-e-AHEAD

This page shows the latest MOV-e-AHEAD news and features for those working in and with pharma, biotech and healthcare.

Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention

Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention

Merck, known as MSD outside the US and Canada, and Ridgeback Biotherapeutics have announced that its MOV-e-AHEAD study has started to enrol its first participants to test antiviral molnupiravir ... It was recently announced that Health Canada will

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Onyx Health

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...
Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...